慢性肝病患者肝自主神经系统病理生理作用及其机制研究进展

doi:10.3969/j.issn.1672-5069.2026.05.002

Abstract

Wang Jiaying, Zhang Mengxiao, Tang Shanhong. Pathophysiological roles and its mechanisms of hepatoautonomic nervous system in patients with chronic liver diseases[J]. Journal of Practical Hepatology, 2026, 29(5): 645-648.

References

[1] Miller B M, Oderberg I M, Goessling W. Hepatic nervous system in development, regeneration, and disease. Hepatology, 2021, 74(6):3513-3522.
[2] Luo Q, Liu P, Dong Y, et al. The role of the hepatic autonomic nervous system. Clin Mol Hepatol, 2023, 29 (4): 1052-1055.
[3] Nagayama I, Kamimura K, Owaki T, et al. Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease. Hepatol Int, 2023, 18 (1): 155-167.
[4] Adori C, Daraio T, Kuiper R, et al. Disorganization and degeneration of liver sympathetic innervations in nonalcoholic fatty liver disease revealed by 3D imaging. Sci Adv, 2021, 7(30):eabg5733.
[5] Kawaguchi T, Tsutsumi T, Nakano D, et al. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res, 2021, 52 (5): 422-432.
[6] Ghosh P M, Shu Z J, Zhu B, et al. Role of β-adrenergic receptors in regulation of hepatic fat accumulation during aging. J Endocrinol, 2012, 213(3):251-261.
[7] Hurr C, Simonyan H, Morgan D A, et al. Liver sympathetic denervation reverses obesity-induced hepatic steatosis. J Physiol, 2019, 597(17):4565-4580.
[8] Amir M, Yu M, He P,et al. Hepatic autonomic nervous system and neurotrophic factors regulate the pathogenesis and progression of non-alcoholic fatty liver disease. Front Med (Lausanne), 2020, 7:62.
[9] 董桂芳,陈杰,李雪梅.自主神经调控参与非酒精性脂肪肝发生发展的相关机制研究进展.北京医学, 2022, 44(10):920-922.
[10] Zheng L, Gong L, Cai X, et al. Sympathetic blockage attenuates fasting-induced hepatic steatosis. Neuroreport, 2022, 33 (17): 763-770.
[11] Fei B, Zhao Y, Wang J,et al. Leveraging adrenergic receptor blockade for enhanced nonalcoholic fatty liver disease treatment via a biomimetic nanoplatform. J Nanobiotechnology, 2024, 22(1):591.
[12] Adori M, Bhat S, Gramignoli R,et al. Hepatic innervations and nonalcoholic fatty liver disease. Semin Liver Dis, 2023, 43(2):149-162.
[13] Xue J, Jiang T, Humaerhan J,et al. Impact of liver sympathetic nervous system on liver fibrosis and regeneration after bile duct ligation in rats. J Mol Neurosci, 2024, 74(1):4.
[14] Medina Pizaño M Y, Loera Arias M J, Montes de Oca Luna R, et al. Neuroimmunomodulation of adrenoblockers during liver cirrhosis: modulation of hepatic stellate cell activity. Ann Med, 2023, 55(1):543-557.
[15] 陈相林,丁珺,程翅,等.交感神经系统在肝硬化及其并发症中的作用研究进展.中国医学科学院学报, 2024, 46(1):128-134.
[16] Mizuno K, Haga H, Okumoto K, et al. Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver. PLoS One, 2021, 16(4): e0249556.
[17] Tanaka M, Jeong J, Thomas C,et al. The sympathetic nervous system promotes hepatic lymphangiogenesis, which is protective against liver fibrosis. Am J Pathol, 2023, 193(12):2182-2202.
[18] Li W, Zhang J, Gao Y, et al. Nervous system in hepatocellular carcinoma: correlation, mechanisms, therapeutic implications, and future perspectives. Biochim Biophys Acta Rev Cancer, 2025, 1880 (3): 189345.
[19] Lelou E, Corlu A, Nesseler N, et al. The role of catecholamines in pathophysiological liver processes. Cells, 2022, 11(6):1021.
[20] Mandal S K, Yadav P, Sheth R A. The neuroimmune axis and its therapeutic potential for primary liver cancer. Int J Mol Sci, 2024, 25(11):6237.
[21] Azzu V, Vacca M, Virtue S, et al. Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology, 2020, 158 (7): 1899-1912.
[22] Hwang J, Okada J, Liu L, et al. The development of hepatic steatosis depends on the presence of liver-innervating parasympathetic cholinergic neurons in mice fed a high-fat diet. PLoS Biol, 2024, 22(10): e3002865.
[23] Li Y, Xu Z, Yu Y, et al. The vagus nerve attenuates fulminant hepatitis by activating the Src kinase in Kuppfer cells. Scand J Immunol, 2014, 79 (2): 105-112.
[24] Ahmed O, Caravaca A S, Crespo M, et al. Hepatic stellate cell activation markers are regulated by the vagus nerve in systemic inflammation. Bioelectron Med, 2023, 9 (1): 6.
[25] Luo L, Xu T, Wang P,et al. Expression of muscarinic acetylcholine receptors in hepatocytes from rat fibrotic liver. Exp Toxicol Pathol, 2017, 69(2):73-81.
[26] Trucas M, Barry D, Conroy M J, et al. Liver innervation in health and disease: neuroimmune-neurovascular interface and future therapeutic implications. Biomedicines, 2025, 13(12):3091.
[27] Trucas M, Kowalik M A, Boi M, et al. The density of hepatic autonomic innervation differs between compensatory and direct hyperplasia rat models. J Peripher Nerv Syst, 2023, 28(1):98-107.
[28] Bauer K C, Ghabra S, Ma C, et al. Liver cancer neuroscience: regulating liver tumors via selective hepatic vagotomy. Methods Protoc, 2024, 7(6):99.
[29] 吴红,刘林,汤善宏.重视肝再生能力在肝衰竭预后评估中的价值.西南医科大学学报, 2024, 47(1):25-28.
[30] 陈美娟,李雪,汤善宏.多维度评估肝功能在肝衰竭患者预后中研究进展.临床军医杂志, 2023, 51(9):901-903+907.
[31] Wang X, Shen C, Yang J,et al. Alpha-fetoprotein as a predictive marker for patients with hepatitis B-related acute-on-chronic liver failure. Can J Gastroenterol Hepatol, 2018, 2018:1232785.
[32] Wang X, Sun M, Yang X,et al. Value of liver regeneration in predicting short-term prognosis for patients with hepatitis B-related acute-on-chronic liver failure. Biomed Res Int, 2020, 2020:5062873.
[33] Kim T H, Um S H, Lee Y S, et al. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy. Aliment Pharmacol Ther, 2022, 55(1):83-96.
[34] Oben J A, Roskams T, Yang S, et al. Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury. Hepatology, 2003, 38 (3): 664-673.
[35] Soeda J, Mouralidarane A, Ray S, et al. Theβ-adrenoceptor agonist isoproterenol rescues acetaminophen-injured livers through increasing progenitor numbers by Wnt in mice. Hepatology, 2014, 60 (3): 1023-1034.
[36] Song Z, Wu J, Jiang T, et al. The protective effect of the vagus nerve-α7nAChR-IL-22 pathway on acute liver injury. Cytokine, 2024, 186:156840.

Pathophysiological roles and its mechanisms of hepatoautonomic nervous system in patients with chronic liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Huang Yin, Mo Jun, Zhuang Xianrui, et al. Endoscopic glue injection and/or esophageal variceal ligation in the treatment of patients with liver cirrhosis complicated with esophageal and gastric variceal bleeding [J]. Journal of Practical Hepatology, 2026, 29(5): 701-704.
[2]	Chen Lihong, Liu Yinhui, Gao Meifang, et al. Clinical efficacy of enteral nutrition preparations in the treatment of patients with decompensated hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2026, 29(5): 705-708.
[3]	Wen Ting, Jia Yuyang, Feng Liuping. Application of liver DWI parameters in predicting patients with liver cirrhosis and high-risk esophageal varices [J]. Journal of Practical Hepatology, 2026, 29(5): 709-712.
[4]	Ru Xiufeng, Qin Lin, Dong Xiaoping. Partial splenic embolization based on highly selective catheterization of splenic artery in the treatment of patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2026, 29(5): 713-716.
[5]	Gao Guimei, Nan Feiyan, Yin Xiaoling, et al. Color Doppler ultrasound and CEUS parameter changes in patients with liver cirrhosis after transjugular intrahepatic portosystemic shunt [J]. Journal of Practical Hepatology, 2026, 29(5): 717-720.
[6]	Feng Dandan, Liu Zihan, Hao Miao, et al. Efficacy and safety of lenvatinib plus camrelizumab at base of TACE in treatment of patients with unresectable hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2026, 29(5): 721-724.
[7]	Zhou Zhonghua, Li Donghui, Bin Pan, et al. Clinical clues of microvessel density exhibited by MSCT perfusion imaging parameters in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2026, 29(5): 725-728.
[8]	Zhu He, Li Yaoji, Wang Rui, et al. Clinical benefits of sintilimab and lenvatinib combination in dealing with patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2026, 29(5): 729-732.
[9]	Wu Hong, Shen Lanchao, Jiang Zhengwei, et al. Comparative study of drug-eluting beads and conventional transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2026, 29(5): 737-740.
[10]	Lai Zhenhui, Cai Yinlian, Cui Dong, et al. Prediction of esophageal gastric varices by abdominal CT scan parameters in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2026, 29(4): 565-568.
[11]	Li Lifang, Wang Chaoyang, Li Zexin. Efficacy of liver stiffness measurement in combination with FIB-4 index and serum CHI3L1 levels in predicting esophageal varices in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2026, 29(4): 569-572.
[12]	Zhu Mengping, Zhang Aiqing, Ning Yueji. Endoscopic varies ligation and tissue glue plus lauromacrogol sandwich therapy in patients with hepatitis B-induced liver cirrhosis and esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2026, 29(4): 573-576.
[13]	Chen Ling, Liu Hong, Zhang Xinling, et al. Assessment of esophageal varices by spectral CT parameters in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2026, 29(4): 577-580.
[14]	Chen Weiwei, Chen Ke, Liu Ping, et al. Clinical effectiveness of TACE in combination with targeted and immunotherapy plus Huai’er granule in treatment of patients with unresectable primary liver cancer [J]. Journal of Practical Hepatology, 2026, 29(4): 585-588.
[15]	Xu Gang, Pan XiaoLin, Wang Ping, et al. Clinical benefits of drug-loaded microsphere transcatheter arterial chemoembolization in treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2026, 29(4): 589-592.